Infections Common in IBD, Rates Vary by Treatment
Patients with inflammatory bowel disease (IBD) experienced higher rates of mild and moderate infections. Women, smokers, those with multiple comorbidities, and those with exposure to certain IBD medications showed significantly higher rates of infections.
METHODOLOGY:
Researchers conducted a prospective observational study (June 2020 to July 2021) to evaluate the incidence of and risk factors for mild, moderate, and severe infections in 629 patients (mean age, 48.3 years; 58.2% women) with IBD who used an established remote monitoring platform for IBD management.
They used the Patient-Reported Infections Questionnaire, a validated seven-item tool with a 3-month recall period, to collect data on 15 infection categories, including respiratory tract, urinary tract, and skin conditions and COVID-19.
The presence or absence of disease activity was confirmed using a combination of monitoring questionnaire scores for patient-reported disease activity and faecal calprotectin levels.
The severity of infection was categorised on the basis of the type and route of treatment as mild (self-limiting or requiring topical treatment), moderate (requiring oral treatment), or severe (requiring hospitalisation and/or intravenous treatment).
Exposure to different medications, alone or in combination, was also assessed.
TAKEAWAY:
Overall, 991 infections were reported during 573.8 person-years of follow-up, with an overall incidence rate (IR) of 172.7 per 100 person-years, predominantly comprising mild (68%; IR, 117.5 per 100 person-years) and moderate (29.5%; IR, 50.9 per 100 person-years) infections.
Women demonstrated significantly higher rates of infections than men (IR ratio [IRR], 1.70; P < .001), with increased rates of infections among current smokers vs non-smokers (IRR, 1.43; P = .004).
Patients with a Charlson Comorbidity Index score > 2 had significantly higher rates of infections than those with lower scores (IRR for all infections, 1.69; P = .031).
Glucocorticoid use more than doubled the rates of infections (IRR, 2.02; P = .033), and compared with no treatment, the use of JAK inhibitors, immunomodulator monotherapy, anti-TNF monotherapy, and combination therapy with anti-TNF and immunomodulators were associated with increased rates of infections.
IN PRACTICE:
"Clinicians should adopt a holistic approach that includes vigilant monitoring, preferably using validated tools, such as the PRIQ [Patient-Reported Infections Questionnaire], to identify patients with frequent mild or moderate infections. In addition, proactive application of preventive strategies, like vaccination, optimizing nutritional status, counselling for lifestyle modifications, and careful selection of therapies, should be used to reduce infection risk," the authors of the study wrote.
SOURCE:
This study was led by Ashkan Rezazadeh Ardabili, MD, Department of Gastroenterology and Hepatology, Maastricht University Medical Centre+, Maastricht, the Netherlands. It was published online on July 09, 2025, in the Journal of Crohn's and Colitis.
LIMITATIONS:
The study's 1‐year follow‐up coincided with COVID‐19 public health measures, likely underestimating overall rates of infections. This study was underpowered to precisely assess rare outcomes, and its real‐world design limited the control over the distribution of medication groups, especially when stratifying the analysis by IBD subtype.
DISCLOSURES:
This study was supported in part by an investigator-initiated research grant from Takeda. Some authors reported receiving grants, non-financial support, and research prizes and serving as speaker, advisor, and/or principal investigator for various institutions and pharmaceutical companies, including Takeda.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 hours ago
- Yahoo
Patient Capital Opportunity Equity Strategy Initiated a Position in UnitedHealth Group Incorporated (UNH) on a Dip
Patient Capital Management, a value investing firm, released its 'Patient Capital Opportunity Equity Strategy' second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The strategy generated a total return of 15.3% net of fees in the quarter compared to the strategy's unmanaged benchmark, the S&P 500 Index's 10.9% return. According to a three-factor performance attribution model, the selection effect contributed positively to the portfolio's performance, which was partially offset by allocation and interaction effects. In addition, you can check the fund's top 5 holdings to know its best picks in 2025. In its second quarter 2025 investor letter, Patient Capital Opportunity Equity Strategy highlighted stocks such as UnitedHealth Group Incorporated (NYSE:UNH). UnitedHealth Group Incorporated (NYSE:UNH) is a diversified healthcare company that operates through UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx segments. The one-month return of UnitedHealth Group Incorporated (NYSE:UNH) was -4.62%, and its shares lost 49.04% of their value over the last 52 weeks. On July 17, 2025, UnitedHealth Group Incorporated (NYSE:UNH) stock closed at $288.07 per share, with a market capitalization of $261.32 billion. Patient Capital Opportunity Equity Strategy stated the following regarding UnitedHealth Group Incorporated (NYSE:UNH) in its second quarter 2025 investor letter: "This quarter we entered five new positions, while exiting three. We initiated a position in UnitedHealth Group Incorporated (NYSE:UNH), one of the largest healthcare companies in the United States, after the stock declined more than 50% from its 2025 highs, reaching multi-year lows. The drop followed a rare misstep in its Medicare Advantage business, where higher-than-expected costs drove margin compression, a cut to EPS and ultimately, the withdrawal of forward guidance. In response, the company announced a leadership change, bringing back former CEO and current Chairman Stephen Hemsley. UNH has long been a market favorite for its consistency in growth, earnings and return on capital. The disappointment led investors to flee. While the short-term outlook remains murky, over the long-term we have confidence the company can improve underwriting margins. With all competitors focused on underwriting to margins, future pricing should be more rational and in line with current usage trends. Rebuilding investor confidence may take time, but we believe UNH's integrated platform and unique asset mix position it to remain a category leader and return to strong returns over time. Following the sell-off, several insiders stepped in to buy stock, most notably Stephen Hemsley with a $25M purchase and the CFO, John Rex, with $5M. The company also has an $8.4B buyback authorization (roughly 3% of shares) and a robust 10% free cash flow yield. Management remains confident in its ability to compound EPS at a 13 16% rate over the long term. We view the recent dislocation as an opportunity to own a high-quality compounder at a compelling valuation." A senior healthcare professional giving advice to a patient in a clinic. UnitedHealth Group Incorporated (NYSE:UNH) is in 18th position on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 139 hedge fund portfolios held UnitedHealth Group Incorporated (NYSE:UNH) at the end of the first quarter, which was 150 in the previous quarter. While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered UnitedHealth Group Incorporated (NYSE:UNH) and shared Vulcan Value Partners' views on the company. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Researchers find a link between gut bacteria and genes in colitis flare-ups
Researchers have identified a gut-genetic interaction that could trigger an overactive immune response in the colon — offering one possible explanation for the pain and bleeding of ulcerative colitis, and why it behaves so differently from patient to patient. Their research is published Friday in the journal Science Immunology. Ulcerative colitis is a chronic disease that affects more than 1.2 million people in the United States, according to a 2023 study of medical claims data. It falls under the umbrella of inflammatory bowel disease, or IBD — a group of conditions that includes Chron's disease and is marked by unpredictable flare-ups, long-term discomfort, and treatments that often work inconsistently. 'This study demonstrates that it's not just an imbalance of microbes in your gut or genetics that induce intestinal inflammation — but the interaction between the two,' said Hisako Kayama, an associate professor of immunology at Osaka University and co-senior author of the study. At the center of that inflammatory response is a protein called STING that helps the body recognize the DNA of bacteria and viruses and mount an immune response. Healthy people are able to keep this response under control with the help of a gene called OTUD3, which acts as a biological brake. But in some people, their OTUD3 gene variant leads that brake to fail — causing the immune system to treat harmless bacteria as a threat. Unchecked, the protein can drive chronic inflammation, particularly in the gut, which is home to many different types of "good" bacteria. The protein STING is very important in fighting bacterial infections, said co-author Dr. Kiyoshi Takeda, a professor of immunology at Osaka University. 'But the problem is that the overactivation of STING causes inflammation.' To explore how this interaction plays out, the researchers studied mice bred specially to have a genetic vulnerability to colitis similar to humans. When feces from the ulcerative colitis patients was transferred to the colons of the mice, they developed more severe colitis symptoms than mice with a normal version of the gene. If they didn't have the gene variant or the microbial trigger, the disease didn't develop. In total, researchers used tissue and gut bacteria from 124 patients — including 65 with ulcerative colitis and 59 with colorectal cancer — plus 12 healthy people as controls. The culprit was a molecule called cGAMP, which is made by certain gut bacteria. In healthy mice, researchers know that OTUD3 helps break down excess cGAMP so the immune system doesn't overreact. But in mice without a working version of that gene, cGAMP built up, overactivating STING and causing inflammation. The findings could help explain why some patients respond poorly to current ulcerative colitis treatments, which typically suppress the immune system as a whole. By pinpointing a single inflammatory pathway, the study opens the door to more precise, personalized therapies — especially for patients who carry this specific gene variant. Still, the researchers caution that any treatment targeting the STING protein directly must be used carefully, since suppressing it too much could leave patients vulnerable to infection. Alternative approaches, such as targeting cGAMP-producing bacteria, could allow STING to keep doing its job in the rest of the body while dialing down inflammation in the colon. The variant gene that colitis sufferers have is common. According to past genome-wide studies, it appears in about 53% of Europeans, 52% of Americans and 16% of Japanese people. Not everyone with it develops the disease, lending credence to the idea that it's the interaction between genes and microbes that triggers inflammation. 'This study is helpful in demonstrating a specific example — a genetic variant and a microbial signal — that leads to inflammation,' said Dr. Jonathan Jacobs, a gastroenterologist and microbiome researcher at UCLA who was not involved with the study. 'That's exciting," he said, because it offers a clear mechanism that ties together many of the risk factors scientists have long observed in inflammatory bowel disease. Even if it turns out not many people are vulnerable to this particular gut-genetic interaction, he said, the research could lead to more personalized treatment. 'It moves us closer to precision medicine,' Jacobs said. The shift toward more targeted treatment could make a world of difference for patients like Anderson Hopley, a volunteer with the Orange County and Los Angeles chapter of the Crohn's and Colitis Foundation who was diagnosed with Crohn's this year. 'I know people who have medication that'll work for a couple years, maybe even just a couple months, and then it kind of randomly stops,' he said. 'They have to adjust everything.' Although Hopley has Crohn's, not ulcerative colitis, he said the new study still resonates. 'I think it'd be really nice to know what causes this,' he said. 'Even if there's not a cure yet, just having an answer — some clarity — would be a step in the right direction.' This story originally appeared in Los Angeles Times. Solve the daily Crossword
New York Times
a day ago
- New York Times
Man Who Was Pulled Into M.R.I. Machine Has Died, Police Say
A man who was critically injured on Wednesday after he entered an M.R.I. room on Long Island and was pulled into the machine by his chain necklace died the next day, the authorities said on Friday. The man, who was 61, was wearing a 'large metallic chain' around his neck when he entered the room at Nassau Open MRI in Westbury, N.Y., at 4:34 p.m. Wednesday, according to the Nassau County Police Department. The man, whom the police did not name, did not have authorization to enter the room, the police said. Being pulled into the machine made him have a medical episode, they said, without offering additional details. He was taken to a hospital, where he died at 2:36 p.m. Thursday, the authorities said. The Nassau County police said in a news release on Friday that the investigation into the episode was continuing. A spokesman for the department said that no other information was available. Nassau Open MRI did not respond to a request for comment. M.R.I. machines use magnets and radio frequency currents to produce detailed anatomical images. The magnetic force of an M.R.I. machine is strong enough to fling a wheelchair across a room, according to the National Institute of Biomedical Imaging and Bioengineering. Patients are advised to remove jewelry and piercings before entering an M.R.I. machine, and people with some medical implants, particularly those containing iron, should not undergo M.R.I. scans, the institute said. Injuries and deaths involving M.R.I. machines have occurred in the past. In 2001, a 6-year-old boy died when a metal oxygen tank was pulled into a machine while he was undergoing a scan. A man died in India in 2018 when he entered an M.R.I. room while carrying an oxygen tank. In 2023, a nurse in California was crushed and needed surgery after she was pinned between an M.R.I. machine and a hospital bed that had been pulled toward the machine by the machine's magnetic force. Nassau Open MRI offers closed and open M.R.I. scans, according to its website. An open M.R.I. involves a machine that is open at the sides rather than a closed tube.
